afn-12520000
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01519492)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Enoyl-ACP reductaseINHIBITOR
Q5TKS5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- afn-12520000
- afn-12520000
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01519492 | Phase 2 | Feb 1, 2012 | Affinium Pharmaceuticals, Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affinium Pharmaceuticals, Ltd | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1